Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

NME1 Drives Expansion of Melanoma Cells with Enhanced Tumor Growth and Metastatic Properties.

Wang Y, Leonard MK, Snyder DE, Fisher ML, Eckert RL, Kaetzel DM.

Mol Cancer Res. 2019 Aug;17(8):1665-1674. doi: 10.1158/1541-7786.MCR-18-0019. Epub 2019 May 23.

PMID:
31123173
2.

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target.

Eckert RL.

Mol Carcinog. 2019 Jun;58(6):837-853. doi: 10.1002/mc.22986. Epub 2019 Mar 28.

PMID:
30693974
3.

NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival.

Grun D, Adhikary G, Eckert RL.

Mol Carcinog. 2019 Apr;58(4):488-499. doi: 10.1002/mc.22943. Epub 2018 Dec 21.

PMID:
30456845
4.

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.

Adhikary G, Grun D, Alexander HR, Friedberg JS, Xu W, Keillor JW, Kandasamy S, Eckert RL.

Oncotarget. 2018 Oct 2;9(77):34495-34505. doi: 10.18632/oncotarget.26130. eCollection 2018 Oct 2.

5.

Chk1 inhibition as a novel therapeutic strategy in melanoma.

Hwang BJ, Adhikary G, Eckert RL, Lu AL.

Oncotarget. 2018 Jul 13;9(54):30450-30464. doi: 10.18632/oncotarget.25765. eCollection 2018 Jul 13.

6.

NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.

Grun D, Adhikary G, Eckert RL.

Oncogene. 2018 Aug;37(34):4711-4722. doi: 10.1038/s41388-018-0290-4. Epub 2018 May 14.

7.

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

Fisher ML, Grun D, Adhikary G, Xu W, Eckert RL.

Oncotarget. 2017 Nov 22;8(66):110257-110272. doi: 10.18632/oncotarget.22628. eCollection 2017 Dec 15.

8.

Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation.

Fisher ML, Ciavattone N, Grun D, Adhikary G, Eckert RL.

Oncotarget. 2017 Aug 27;8(43):73407-73418. doi: 10.18632/oncotarget.20562. eCollection 2017 Sep 26.

9.

Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Akbar A, McNeil NMR, Albert MR, Ta V, Adhikary G, Bourgeois K, Eckert RL, Keillor JW.

J Med Chem. 2017 Sep 28;60(18):7910-7927. doi: 10.1021/acs.jmedchem.7b01070. Epub 2017 Sep 14.

10.

Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.

Saha K, Fisher ML, Adhikary G, Grun D, Eckert RL.

Carcinogenesis. 2017 Aug 1;38(8):827-836. doi: 10.1093/carcin/bgx044.

11.

Transglutaminase 2 Is a Direct Target Gene of YAP-TAZ-Response.

Fisher ML, Adhikary G, Kerr C, Grun D, Eckert RL.

Cancer Res. 2017 Sep 1;77(17):4736. doi: 10.1158/0008-5472.CAN-17-1255. Epub 2017 Aug 15. No abstract available. Erratum in: Cancer Res. 2018 May 15;78(10 ):2775.

12.

Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma.

Kerr C, Adhikary G, Grun D, George N, Eckert RL.

Mol Carcinog. 2018 Jan;57(1):3-11. doi: 10.1002/mc.22714. Epub 2017 Aug 28.

13.

Loss of epidermal AP1 transcription factor function reduces filaggrin level, alters chemokine expression and produces an ichthyosis-related phenotype.

Young CA, Rorke EA, Adhikary G, Xu W, Eckert RL.

Cell Death Dis. 2017 Jun 1;8(6):e2840. doi: 10.1038/cddis.2017.238.

14.

Embryonic AP1 Transcription Factor Deficiency Causes a Collodion Baby-Like Phenotype.

Young CA, Eckert RL, Adhikary G, Crumrine D, Elias PM, Blumenberg M, Rorke EA.

J Invest Dermatol. 2017 Sep;137(9):1868-1877. doi: 10.1016/j.jid.2017.04.032. Epub 2017 May 16.

15.

Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.

Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H.

Ann Surg Oncol. 2017 Aug;24(8):2259-2265. doi: 10.1245/s10434-017-5834-2. Epub 2017 Mar 21.

PMID:
28324285
16.

Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.

Kerr C, Szmacinski H, Fisher ML, Nance B, Lakowicz JR, Akbar A, Keillor JW, Lok Wong T, Godoy-Ruiz R, Toth EA, Weber DJ, Eckert RL.

Oncogene. 2017 May 25;36(21):2981-2990. doi: 10.1038/onc.2016.452. Epub 2016 Dec 12.

17.

Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.

Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, Eckert RL.

Cancer Res. 2016 Dec 15;76(24):7265-7276. Epub 2016 Oct 25.

18.

VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors.

Grun D, Adhikary G, Eckert RL.

Oncogene. 2016 Aug 18;35(33):4379-87. doi: 10.1038/onc.2015.507. Epub 2016 Jan 25.

19.

MEP50/PRMT5 Reduces Gene Expression by Histone Arginine Methylation and this Is Reversed by PKCδ/p38δ Signaling.

Saha K, Adhikary G, Eckert RL.

J Invest Dermatol. 2016 Jan;136(1):214-224. doi: 10.1038/JID.2015.400.

20.

The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.

Fisher ML, Adhikary G, Grun D, Kaetzel DM, Eckert RL.

Mol Carcinog. 2016 Dec;55(12):2024-2036. doi: 10.1002/mc.22448. Epub 2015 Dec 23. Erratum in: Mol Carcinog. 2017 Dec;56(12 ):2718-2720.

21.

Transglutaminase is a tumor cell and cancer stem cell survival factor.

Eckert RL, Fisher ML, Grun D, Adhikary G, Xu W, Kerr C.

Mol Carcinog. 2015 Oct;54(10):947-58. doi: 10.1002/mc.22375. Epub 2015 Aug 10. Review.

22.

Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells.

Hsu TH, Jiang SY, Chang WL, Eckert RL, Scharadin TM, Chang TC.

Cell Death Differ. 2015 Sep;22(9):1561. doi: 10.1038/cdd.2015.90. No abstract available.

23.

Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.

Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL.

Oncotarget. 2015 Aug 21;6(24):20525-39.

24.

Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.

Adhikary G, Grun D, Balasubramanian S, Kerr C, Huang JM, Eckert RL.

Carcinogenesis. 2015 Jul;36(7):800-10. doi: 10.1093/carcin/bgv064. Epub 2015 May 12.

25.

Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.

Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C.

Mol Cancer Res. 2015 Jul;13(7):1083-94. doi: 10.1158/1541-7786.MCR-14-0685-T. Epub 2015 May 1.

26.

Methylosome Protein 50 and PKCδ/p38δ Protein Signaling Control Keratinocyte Proliferation via Opposing Effects on p21Cip1 Gene Expression.

Saha K, Eckert RL.

J Biol Chem. 2015 May 22;290(21):13521-30. doi: 10.1074/jbc.M115.642868. Epub 2015 Apr 7.

27.

The Bmi-1 helix-turn and ring finger domains are required for Bmi-1 antagonism of (-) epigallocatechin-3-gallate suppression of skin cancer cell survival.

Balasubramanian S, Scharadin TM, Han B, Xu W, Eckert RL.

Cell Signal. 2015 Jul;27(7):1336-44. doi: 10.1016/j.cellsig.2015.03.021. Epub 2015 Apr 2.

28.

Structural and biochemical changes underlying a keratoderma-like phenotype in mice lacking suprabasal AP1 transcription factor function.

Rorke EA, Adhikary G, Young CA, Rice RH, Elias PM, Crumrine D, Meyer J, Blumenberg M, Eckert RL.

Cell Death Dis. 2015 Feb 19;6:e1647. doi: 10.1038/cddis.2015.21.

29.

Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells.

Hsu TH, Jiang SY, Chang WL, Eckert RL, Scharadin TM, Chang TC.

Cell Death Differ. 2015 May;22(5):801-14. doi: 10.1038/cdd.2014.175. Epub 2014 Nov 7. Erratum in: Cell Death Differ. 2015 Sep;22(9):1561. Chan, W-L [corrected to Chang, W-L].

30.

Suppressing AP1 factor signaling in the suprabasal epidermis produces a keratoderma phenotype.

Rorke EA, Adhikary G, Young CA, Roop DR, Eckert RL.

J Invest Dermatol. 2015 Jan;135(1):170-180. doi: 10.1038/jid.2014.310. Epub 2014 Aug 22.

31.

Transglutaminase regulation of cell function.

Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K.

Physiol Rev. 2014 Apr;94(2):383-417. doi: 10.1152/physrev.00019.2013. Review.

32.

p38δ regulates p53 to control p21Cip1 expression in human epidermal keratinocytes.

Saha K, Adhikary G, Kanade SR, Rorke EA, Eckert RL.

J Biol Chem. 2014 Apr 18;289(16):11443-53. doi: 10.1074/jbc.M113.543165. Epub 2014 Mar 5.

33.

TIG3: an important regulator of keratinocyte proliferation and survival.

Scharadin TM, Eckert RL.

J Invest Dermatol. 2014 Jul;134(7):1811-1816. doi: 10.1038/jid.2014.79. Epub 2014 Mar 6. Review.

34.

Pericentrosomal localization of the TIG3 tumor suppressor requires an N-terminal hydrophilic region motif.

Scharadin TM, Adhikary G, Shaw K, Grun DJB, Xu W, Eckert RL.

J Invest Dermatol. 2014 May;134(5):1220-1229. doi: 10.1038/jid.2013.533. Epub 2013 Dec 13.

35.

Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation.

Adhikary G, Grun D, Kerr C, Balasubramanian S, Rorke EA, Vemuri M, Boucher S, Bickenbach JR, Hornyak T, Xu W, Fisher ML, Eckert RL.

PLoS One. 2013 Dec 20;8(12):e84324. doi: 10.1371/journal.pone.0084324. eCollection 2013.

36.

Maternal hyperglycemia activates an ASK1-FoxO3a-caspase 8 pathway that leads to embryonic neural tube defects.

Yang P, Li X, Xu C, Eckert RL, Reece EA, Zielke HR, Wang F.

Sci Signal. 2013 Aug 27;6(290):ra74. doi: 10.1126/scisignal.2004020.

37.

Epigenetic cancer prevention mechanisms in skin cancer.

Saha K, Hornyak TJ, Eckert RL.

AAPS J. 2013 Oct;15(4):1064-71. doi: 10.1208/s12248-013-9513-3. Epub 2013 Aug 1. Review.

38.

AP1 transcription factors in epidermal differentiation and skin cancer.

Eckert RL, Adhikary G, Young CA, Jans R, Crish JF, Xu W, Rorke EA.

J Skin Cancer. 2013;2013:537028. doi: 10.1155/2013/537028. Epub 2013 May 23.

39.

Protein kinase C δ increases Kruppel-like factor 4 protein, which drives involucrin gene transcription in differentiating keratinocytes.

Chew YC, Adhikary G, Xu W, Wilson GM, Eckert RL.

J Biol Chem. 2013 Jun 14;288(24):17759-68. doi: 10.1074/jbc.M113.477133. Epub 2013 Apr 17.

40.

A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level.

Balasubramanian S, Kanade S, Han B, Eckert RL.

J Biol Chem. 2012 Oct 19;287(43):36179-89. doi: 10.1074/jbc.M112.359281. Epub 2012 Aug 29.

41.

Biochemistry of epidermal stem cells.

Eckert RL, Adhikary G, Balasubramanian S, Rorke EA, Vemuri MC, Boucher SE, Bickenbach JR, Kerr C.

Biochim Biophys Acta. 2013 Feb;1830(2):2427-34. doi: 10.1016/j.bbagen.2012.07.002. Epub 2012 Jul 20. Review.

42.

Suppression of AP1 transcription factor function in keratinocyte suppresses differentiation.

Han B, Rorke EA, Adhikary G, Chew YC, Xu W, Eckert RL.

PLoS One. 2012;7(5):e36941. doi: 10.1371/journal.pone.0036941. Epub 2012 May 23.

43.

Reduction in embryonic malformations and alleviation of endoplasmic reticulum stress by nitric oxide synthase inhibition in diabetic embryopathy.

Zhao Z, Eckert RL, Reece EA.

Reprod Sci. 2012 Aug;19(8):823-31. doi: 10.1177/1933719111434543. Epub 2012 Apr 24.

44.

The essential role of protein kinase Cδ in diabetes-induced neural tube defects.

Cao Y, Zhao Z, Eckert RL, Reece EA.

J Matern Fetal Neonatal Med. 2012 Oct;25(10):2020-4. doi: 10.3109/14767058.2012.677963. Epub 2012 Apr 21.

45.

TIG3 interaction at the centrosome alters microtubule distribution and centrosome function.

Scharadin TM, Jiang H, Martin S, Eckert RL.

J Cell Sci. 2012 Jun 1;125(Pt 11):2604-14. doi: 10.1242/jcs.096495. Epub 2012 Mar 16.

46.

Sulforaphane induction of p21(Cip1) cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent.

Chew YC, Adhikary G, Wilson GM, Xu W, Eckert RL.

J Biol Chem. 2012 May 11;287(20):16168-78. doi: 10.1074/jbc.M111.305292. Epub 2012 Mar 15.

47.

Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cδ- and p38δ-dependent signaling and keratinocyte differentiation.

Kanade SR, Eckert RL.

J Biol Chem. 2012 Mar 2;287(10):7313-23. doi: 10.1074/jbc.M111.331660. Epub 2011 Dec 23.

48.

Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.

Wilhelmus MM, de Jager M, Rozemuller AJ, Brevé J, Bol JG, Eckert RL, Drukarch B.

J Pathol. 2012 Jan;226(1):132-42. doi: 10.1002/path.2984. Epub 2011 Oct 18.

49.

TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells.

Scharadin TM, Jiang H, Jans R, Rorke EA, Eckert RL.

PLoS One. 2011;6(8):e23230. doi: 10.1371/journal.pone.0023230. Epub 2011 Aug 17.

50.

Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells.

Balasubramanian S, Chew YC, Eckert RL.

Mol Pharmacol. 2011 Nov;80(5):870-8. doi: 10.1124/mol.111.072363. Epub 2011 Aug 1.

Supplemental Content

Loading ...
Support Center